Clinical Trials Sponsored by Inflazyme Pharmaceuticals Ltd

Total 4404 results

Idorsia Pharmaceuticals Ltd.

Completed

The Effect of Reduced Liver Function on Selatogrel Pharmacokinetics

Healthy Subjects | Hepatic Impairment

Germany
Idorsia Pharmaceuticals Ltd.

Completed

To Study the Effect of Cenerimod on the Electrical Activity of the Heart, in Men and Women. To Study the Effect of Cenerimod on the Use of Oral Contraceptives in Women. To Study the Effect That Charcoal Has on the Elimination of Cenerimod From the Body, in Women and Men.

Healthy Subjects

France
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Investigate the Effect of Itraconazole on the Way the Body Absorbs, Distributes, and Gets Rid of ACT-1004-1239 Given as a Single Dose of 10 mg to Healthy Male Subjects

Healthy

Portugal
AFT Pharmaceuticals, Ltd.

Completed

Maxigesic® IV Phase 3 Exposure Study

Postoperative Pain

United States, New Zealand
Neurim Pharmaceuticals Ltd.

Withdrawn

Efficacy and Safety of Slenyto for Insomnia in Children With ASD (ASD)

Autism Spectrum Disorder
Idorsia Pharmaceuticals Ltd.

Completed

Study of the Way the Body Takes up, Distributes, and Gets Rid of ACT-541468 in Subjects With Abnormal Kidney Function Compared to Healthy Subjects

Healthy | Renal Insufficiency

Germany
Avraham Pharmaceuticals Ltd

Completed

Safety and Efficacy Study of Ladostigil in Mild to Moderate Probable Alzheimer's Disease

Cognitive Impairment | Dementia | Alzheimer's Disease | Memory Loss

Austria, Croatia, Germany, Serbia, Spain
Clarity Pharmaceuticals Ltd

Completed

An Imaging Study of 64Cu-SARTATE Using Positron Emission Tomography in Patients With Neuroendocrine Tumours

Neuroendocrine Tumors
Idorsia Pharmaceuticals Ltd.

Completed

Single Oral Dose of 4 mg Cenerimod in Healthy Japanese and Caucasian Subjects

Healthy Volunteers

United States
Idorsia Pharmaceuticals Ltd.

Completed

Efficacy and Safety of ACT-541468 in Elderly Subjects With Insomnia Disorder

Insomnia Disorder

United States, Germany
Idorsia Pharmaceuticals Ltd.

Completed

Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of ACT-334441 in Subjects With Systemic Lupus Erythematosus

Systemic Lupus Erythematosus

United States, Belarus, Bulgaria, Georgia, Russian Federation, Ukraine
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of ACT-1004-1239 in Healthy Male Subjects

Healthy

United States
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Evaluate the Effects of ACT-541468 on Respiration in Patients With Moderate Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

Germany
Idorsia Pharmaceuticals Ltd.

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-451840 in Healthy Subjects (Part A)

Healthy

France
Idorsia Pharmaceuticals Ltd.

Completed

Study to Validate the Questionnaire Called IDSIQ™ in Patients With Insomnia Disorder

Insomnia Disorder

United States, Germany
AFT Pharmaceuticals, Ltd.

Completed

Maxigesic 325 Acute Dental Pain Study

Dental Pain

United States, New Zealand
Atlantic Pharmaceuticals Ltd

Completed

Phase 1 Food Effect Study for Alicaforsen Tablets

IBD

United Kingdom
Idorsia Pharmaceuticals Ltd.

Completed

A Study in Healthy Male Subjects to Investigate Whether Administration of Rifampicin Can Affect the Fate of Clazosentan in the Body of Clazosentan

Healthy Subjects

Netherlands
Idorsia Pharmaceuticals Ltd.

Completed

Essential Hypertension (REDUCE-1)

Essential Hypertension

Israel, Serbia
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Assess the Tolerability, Safety, Pharmacodynamics, and Pharmacokinetics of Ascending Single Doses (Including Food Interaction) and Ascending Multiple Doses of ACT-453859, and Multiple Doses of Setipiprant (ACT-129968)

Healthy
Idorsia Pharmaceuticals Ltd.

Completed

Clinical Study to Assess the Pharmacokinetics, Safety, and Tolerability of ACT-129968 in Healthy Subjects

Healthy Subjects

Germany
Idorsia Pharmaceuticals Ltd.

Completed

A Study of ACT-541468 in Healthy Japanese and Caucasian Subjects

Healthy Subjects

Netherlands
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of ACT-541468 in Healthy Young Adults and Elderly Subjects

Healthy Subjects

Netherlands
Idorsia Pharmaceuticals Ltd.

Completed

A Study Conducted in Healthy Male Subjects to Investigate the Safety and Tolerability of AC-76, Its Fate in the Body, and Its Effect on the Body

Healthy Subjects

United States
Idorsia Pharmaceuticals Ltd.

Completed

Tezosentan in Acute Heart Failure (VERITAS 1)

Acute Heart Failure | Acute Decompensation of Chronic Heart Failure | New Onset of Heart Failure

United States, United Kingdom, Israel, Switzerland, Austria, Denmark, France, Germany, Greece, Poland
Idorsia Pharmaceuticals Ltd.

Completed

Clinical Study to Explore the Efficacy of ACT-129968 in Patients With Partly Controlled Asthma (CONTROL)

Asthma

United States, Australia, Bulgaria, Germany, Hungary, Israel, Poland, Russian Federation, Serbia, Singapore, South Africa, Sweden, Ukraine
Idorsia Pharmaceuticals Ltd.

Completed

Pharmacokinetic Interaction Between Midazolam and ID-082 in Healthy Subjects

Healthy

United Kingdom
Neurim Pharmaceuticals Ltd.

Completed

Efficacy and Safety of Circadin® 2 mg in the Treatment of Primary Insomnia Patients

Primary Insomnia

United Kingdom
Avraham Pharmaceuticals Ltd

Completed

A 3 Year Study to Evaluate the Safety and Efficacy of Low Dose Ladostigil in Patients With Mild Cognitive Impairment

Dementia | Mild Cognitive Impairment

Germany, Austria, Israel
BiondVax Pharmaceuticals ltd.

Completed

Phase II Study to Assess Safety & Immunogenicity of Multimeric-001 Influenza Vaccine, Followed by TIV (BVX006)

Influenza

Israel
AFT Pharmaceuticals, Ltd.

Withdrawn

Maxi-Analgesic Osteoarthritis (OA) Study

Osteoarthritis
Faron Pharmaceuticals Ltd

Completed

Safety, Tolerability and Preliminary Efficacy of FP-1201 in ALI and ARDS. Phase I/II

Acute Respiratory Distress Syndrome | Acute Lung Injury

United Kingdom
BiondVax Pharmaceuticals ltd.

Completed

A Study to Assess the Safety and Immunogenicity of M-001 Influenza Vaccine as a Primer to TIV in Elderly Volunteers

Healthy | Influenza

Israel
AFT Pharmaceuticals, Ltd.

Withdrawn

Maxi-Analgesic Phase 2 Study to Compare the Analgesic Effects in Different Dosing Groups to Treat Teeth Extraction Pain

Dental Pain

United States
BiondVax Pharmaceuticals ltd.

Completed

A Double-Dose Safety Study of An Influenza Vaccine (Multimeric-001) Injected to Elderly Volunteers

Influenza

Israel
Sauflon Pharmaceuticals Ltd

Completed

Clinical Performance of All-in-One Light Multi-purpose for Silicone Hydrogel Contact Lenses

Healthy

United Kingdom
Neurim Pharmaceuticals Ltd.

Completed

Sleep Inducing And Maintaining Efficacy Of Circadin In Elderly Insomniacs (Neu I)

Primary Insomnia

France
Ono Pharmaceutical Co. Ltd
Kyorin Pharmaceutical Co.,Ltd

Completed

Long-term Safety and Efficacy of Imidafenacin in Patients With Overactive Bladder

Overactive Bladder

Japan
BioGene Pharmaceutical Ltd.

Withdrawn

Safety, Tolerability and Efficacy of Vaginal Suppositories for Treatment of the Endometriosis (ELTA)

Endometriosis | Endometriosis Ovary | Endometriosis, Rectum | Endometriosis Externa

Switzerland
Ferring Pharmaceuticals
Ferring Pharmaceuticals Korea, Ltd.

Completed

Efficacy and Safety of Degarelix One Month Dosing Regimen in Korean Patients With Prostate Cancer

Prostate Cancer

Korea, Republic of
Ferring Pharmaceuticals
Ferring Pharmaceuticals Korea, Ltd.

Completed

Long-Term Safety and Tolerability of Degarelix One-Month Dosing Regimen in Korean Patients

Prostate Cancer

Korea, Republic of
Telix Pharmaceuticals (Innovations) Pty Limited
Grand Pharmaceutical (China) Co., Ltd.

Recruiting

68Ga-PSMA-11 Efficacy in Detecting BCR Prostate Cancer in Chinese Patients

Prostate Cancer | Biochemical Recurrence of Malignant Neoplasm of Prostate | BCR Prostate Carcinoma

China
Dizal (Jiangsu) Pharmaceutical Co., Ltd.
PPD Development, L.P.

Recruiting

DZD9008 PK Study in Hepatic Impairment Subjects

Hepatic Impairment

United States
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Recruiting

Bioequivalence With Clinical Endpoint Study of Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 mcg Inhalation Powder/GSK in Patients With Asthma (AERO-PD)

Asthma

Greece
Persica Pharmaceuticals Ltd
Micron Research Ltd

Active, not recruiting

Persica 002 Phase 1b PP353 vs Placebo in the Treatment of Low Back Pain

Chronic Low-back Pain

Spain, United Kingdom, New Zealand, Denmark
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Completed

A Clinical Trial for Examining the Therapeutic Equivalence Between Fluticasone Propionate 100 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals vs. FLOVENT DISKUS® 100mcg/Blister Oral Inhalation Powder/GSK in Patients With Asthma (ANASSA-PD)

Asthma

Greece
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Active, not recruiting

A Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers

Asthma | Bioequivalence

Greece
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Completed

A Pilot Bioequivalence Study Between Fluticasone Propionate 500 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 500/50 Inhalation Powder/GSK in Healthy Volunteers

Bioequivalence

Greece
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Completed

A Pivotal Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers

Bioequivalence

Greece
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Completed

A Bioequivalence Study Between Fluticasone and Salmeterol vs. SERETIDE DISKUS® in Healthy Volunteers With Charcoal Blockade

Bioequivalence

Greece

3

Subscribe